Comparison of diagnostic accuracy of In-111-pentetreotide SPECT and Ga-68-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours

S. Van Binnebeek; B. Vanbilloen; K. Baete; C. Terwinghe; M. Koole; F. M. Mottaghy; P. M. Clement; L. Mortelmans; K. Bogaerts; K. Haustermans; K. Nackaerts; E. Van Cutsem; C. Verslype; A. Verbruggen; C. M. Deroose

doi:10.1007/s00330-015-3882-1

Comparison of diagnostic accuracy of In-111-pentetreotide SPECT and Ga-68-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours

S. Van Binnebeek, B. Vanbilloen, K. Baete, C. Terwinghe, M. Koole, F. M. Mottaghy, P. M. Clement, L. Mortelmans, K. Bogaerts, K. Haustermans, K. Nackaerts, E. Van Cutsem, C. Verslype, A. Verbruggen, C. M. Deroose^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

61 Citations (Web of Science)

Abstract

To compare the diagnostic accuracy of In-111-pentetreotide-scintigraphy with Ga-68-DOTATOC-positron emission tomography (PET)/computed tomography (CT) in patients with metastatic-neuroendocrine tumour (NET) scheduled for peptide receptor radionuclide therapy (PRRT). Incremental lesions (ILs) were defined as lesions observed on only one modality. Fifty-three metastatic-NET-patients underwent In-111-pentetreotide-scintigraphy (24 h post-injection; planar+single-photon emission CT (SPECT) abdomen) and whole-body Ga-68-DOTATOC-PET/CT. SPECT and PET were compared in a lesion-by-lesion and organ-by-organ analysis, determining the total lesions and ILs for both modalities. Significantly more lesions were detected on Ga-68-DOTATOC-PET/CT versus In-111-pentetreotide-scintigraphy. More specifically, we observed 1,098 lesions on PET/CT (range: 1-105; median: 15) versus 660 on SPECT (range: 0-73, median: 9) (p <0.0001), with 439 PET-ILs (42/53 patients) and one SPECT-IL (1/53 patients). The sensitivity for PET/CT was 99.9 % (95 % CI, 99.3-100.0), for SPECT 60.0 % (95 % CI, 48.5-70.2). The organ-by-organ analysis showed that the PET-ILs were most frequently visualized in liver and skeleton. Ga-DOTATOC-PET/CT is superior for the detection of NET-metastases compared to In-111-pentetreotide SPECT. aEuro cent Somatostatin receptor PET is superior to SPECT in detecting NET metastases aEuro cent PET is the scintigraphic method for accurate depiction of NET tumour burden aEuro cent The sensitivity of PET is twofold higher than the sensitivity of SPECT.

Original language	English
Pages (from-to)	900-909
Journal	European Radiology
Volume	26
Issue number	3
DOIs	https://doi.org/10.1007/s00330-015-3882-1
Publication status	Published - Mar 2016

Keywords

Ga-68-DOTATOC
In-111-pentetreotide
SPECT
PRRT
Neuroendocrine tumour

Access to Document

10.1007/s00330-015-3882-1

Cite this

Van Binnebeek, S., Vanbilloen, B., Baete, K., Terwinghe, C., Koole, M., Mottaghy, F. M., Clement, P. M., Mortelmans, L., Bogaerts, K., Haustermans, K., Nackaerts, K., Van Cutsem, E., Verslype, C., Verbruggen, A., & Deroose, C. M. (2016). Comparison of diagnostic accuracy of In-111-pentetreotide SPECT and Ga-68-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. European Radiology, 26(3), 900-909. https://doi.org/10.1007/s00330-015-3882-1

@article{5b6624b14d2e43848f2ae77826a79284,

title = "Comparison of diagnostic accuracy of In-111-pentetreotide SPECT and Ga-68-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours",

abstract = "To compare the diagnostic accuracy of In-111-pentetreotide-scintigraphy with Ga-68-DOTATOC-positron emission tomography (PET)/computed tomography (CT) in patients with metastatic-neuroendocrine tumour (NET) scheduled for peptide receptor radionuclide therapy (PRRT). Incremental lesions (ILs) were defined as lesions observed on only one modality. Fifty-three metastatic-NET-patients underwent In-111-pentetreotide-scintigraphy (24 h post-injection; planar+single-photon emission CT (SPECT) abdomen) and whole-body Ga-68-DOTATOC-PET/CT. SPECT and PET were compared in a lesion-by-lesion and organ-by-organ analysis, determining the total lesions and ILs for both modalities. Significantly more lesions were detected on Ga-68-DOTATOC-PET/CT versus In-111-pentetreotide-scintigraphy. More specifically, we observed 1,098 lesions on PET/CT (range: 1-105; median: 15) versus 660 on SPECT (range: 0-73, median: 9) (p <0.0001), with 439 PET-ILs (42/53 patients) and one SPECT-IL (1/53 patients). The sensitivity for PET/CT was 99.9 % (95 % CI, 99.3-100.0), for SPECT 60.0 % (95 % CI, 48.5-70.2). The organ-by-organ analysis showed that the PET-ILs were most frequently visualized in liver and skeleton. Ga-DOTATOC-PET/CT is superior for the detection of NET-metastases compared to In-111-pentetreotide SPECT. aEuro cent Somatostatin receptor PET is superior to SPECT in detecting NET metastases aEuro cent PET is the scintigraphic method for accurate depiction of NET tumour burden aEuro cent The sensitivity of PET is twofold higher than the sensitivity of SPECT.",

keywords = "Ga-68-DOTATOC, In-111-pentetreotide, SPECT, PRRT, Neuroendocrine tumour",

author = "{Van Binnebeek}, S. and B. Vanbilloen and K. Baete and C. Terwinghe and M. Koole and Mottaghy, {F. M.} and Clement, {P. M.} and L. Mortelmans and K. Bogaerts and K. Haustermans and K. Nackaerts and {Van Cutsem}, E. and C. Verslype and A. Verbruggen and Deroose, {C. M.}",

year = "2016",

month = mar,

doi = "10.1007/s00330-015-3882-1",

language = "English",

volume = "26",

pages = "900--909",

journal = "European Radiology",

issn = "0938-7994",

publisher = "Springer, Cham",

number = "3",

}

Van Binnebeek, S, Vanbilloen, B, Baete, K, Terwinghe, C, Koole, M, Mottaghy, FM, Clement, PM, Mortelmans, L, Bogaerts, K, Haustermans, K, Nackaerts, K, Van Cutsem, E, Verslype, C, Verbruggen, A & Deroose, CM 2016, 'Comparison of diagnostic accuracy of In-111-pentetreotide SPECT and Ga-68-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours', European Radiology, vol. 26, no. 3, pp. 900-909. https://doi.org/10.1007/s00330-015-3882-1

TY - JOUR

T1 - Comparison of diagnostic accuracy of In-111-pentetreotide SPECT and Ga-68-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours

AU - Van Binnebeek, S.

AU - Vanbilloen, B.

AU - Baete, K.

AU - Terwinghe, C.

AU - Koole, M.

AU - Mottaghy, F. M.

AU - Clement, P. M.

AU - Mortelmans, L.

AU - Bogaerts, K.

AU - Haustermans, K.

AU - Nackaerts, K.

AU - Van Cutsem, E.

AU - Verslype, C.

AU - Verbruggen, A.

AU - Deroose, C. M.

PY - 2016/3

Y1 - 2016/3

N2 - To compare the diagnostic accuracy of In-111-pentetreotide-scintigraphy with Ga-68-DOTATOC-positron emission tomography (PET)/computed tomography (CT) in patients with metastatic-neuroendocrine tumour (NET) scheduled for peptide receptor radionuclide therapy (PRRT). Incremental lesions (ILs) were defined as lesions observed on only one modality. Fifty-three metastatic-NET-patients underwent In-111-pentetreotide-scintigraphy (24 h post-injection; planar+single-photon emission CT (SPECT) abdomen) and whole-body Ga-68-DOTATOC-PET/CT. SPECT and PET were compared in a lesion-by-lesion and organ-by-organ analysis, determining the total lesions and ILs for both modalities. Significantly more lesions were detected on Ga-68-DOTATOC-PET/CT versus In-111-pentetreotide-scintigraphy. More specifically, we observed 1,098 lesions on PET/CT (range: 1-105; median: 15) versus 660 on SPECT (range: 0-73, median: 9) (p <0.0001), with 439 PET-ILs (42/53 patients) and one SPECT-IL (1/53 patients). The sensitivity for PET/CT was 99.9 % (95 % CI, 99.3-100.0), for SPECT 60.0 % (95 % CI, 48.5-70.2). The organ-by-organ analysis showed that the PET-ILs were most frequently visualized in liver and skeleton. Ga-DOTATOC-PET/CT is superior for the detection of NET-metastases compared to In-111-pentetreotide SPECT. aEuro cent Somatostatin receptor PET is superior to SPECT in detecting NET metastases aEuro cent PET is the scintigraphic method for accurate depiction of NET tumour burden aEuro cent The sensitivity of PET is twofold higher than the sensitivity of SPECT.

AB - To compare the diagnostic accuracy of In-111-pentetreotide-scintigraphy with Ga-68-DOTATOC-positron emission tomography (PET)/computed tomography (CT) in patients with metastatic-neuroendocrine tumour (NET) scheduled for peptide receptor radionuclide therapy (PRRT). Incremental lesions (ILs) were defined as lesions observed on only one modality. Fifty-three metastatic-NET-patients underwent In-111-pentetreotide-scintigraphy (24 h post-injection; planar+single-photon emission CT (SPECT) abdomen) and whole-body Ga-68-DOTATOC-PET/CT. SPECT and PET were compared in a lesion-by-lesion and organ-by-organ analysis, determining the total lesions and ILs for both modalities. Significantly more lesions were detected on Ga-68-DOTATOC-PET/CT versus In-111-pentetreotide-scintigraphy. More specifically, we observed 1,098 lesions on PET/CT (range: 1-105; median: 15) versus 660 on SPECT (range: 0-73, median: 9) (p <0.0001), with 439 PET-ILs (42/53 patients) and one SPECT-IL (1/53 patients). The sensitivity for PET/CT was 99.9 % (95 % CI, 99.3-100.0), for SPECT 60.0 % (95 % CI, 48.5-70.2). The organ-by-organ analysis showed that the PET-ILs were most frequently visualized in liver and skeleton. Ga-DOTATOC-PET/CT is superior for the detection of NET-metastases compared to In-111-pentetreotide SPECT. aEuro cent Somatostatin receptor PET is superior to SPECT in detecting NET metastases aEuro cent PET is the scintigraphic method for accurate depiction of NET tumour burden aEuro cent The sensitivity of PET is twofold higher than the sensitivity of SPECT.

KW - Ga-68-DOTATOC

KW - In-111-pentetreotide

KW - SPECT

KW - PRRT

KW - Neuroendocrine tumour

U2 - 10.1007/s00330-015-3882-1

DO - 10.1007/s00330-015-3882-1

M3 - Article

C2 - 26162577

VL - 26

SP - 900

EP - 909

JO - European Radiology

JF - European Radiology

SN - 0938-7994

IS - 3

ER -